My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 116

    1.

    Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.

    Obrosova IG, Pacher P, Szabó C, Zsengeller Z, Hirooka H, Stevens MJ, Yorek MA.

    Diabetes. 2005 Jan;54(1):234-42.PMID: 15616034 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.

    Drel VR, Pacher P, Stevens MJ, Obrosova IG.

    Free Radic Biol Med. 2006 Apr 15;40(8):1454-65. Epub 2006 Jan 31.PMID: 16631535 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.

    Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, Obrosova IG.

    Int J Mol Med. 2008 Jun;21(6):667-76.PMID: 18506358 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.

    Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ.

    Diabetes. 2003 Mar;52(3):864-71.PMID: 12606532 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.

    Obrosova IG, Drel VR, Pacher P, Ilnytska O, Wang ZQ, Stevens MJ, Yorek MA.

    Diabetes. 2005 Dec;54(12):3435-41.PMID: 16306359 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effect of fidarestat and alpha-lipoic acid on diabetes-induced epineurial arteriole vascular dysfunction.

    Yorek MA, Coppey LJ, Gellett JS, Davidson EP, Lund DD.

    Exp Diabesity Res. 2004 Apr-Jun;5(2):123-35.PMID: 15203883 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.

    Li F, Szabó C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T, Stevens MJ, Obrosova IG.

    Diabetologia. 2004 Apr;47(4):710-7.PMID: 15298348 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve.

    Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA.

    Diabetes. 2001 Aug;50(8):1927-37.PMID: 11473057 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.

    Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Yorek MA.

    Int J Exp Diabetes Res. 2002;3(1):21-36.PMID: 11900277 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.

    Kuzumoto Y, Kusunoki S, Kato N, Kihara M, Low PA.

    Diabetologia. 2006 Dec;49(12):3085-93. Epub 2006 Oct 25.PMID: 17063327 [PubMed - indexed for MEDLINE]Related articles

    11.

    Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve.

    Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA.

    Int J Exp Diabetes Res. 2000;1(2):131-43.PMID: 11469397 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.

    Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, Chung SK.

    Diabetes. 2006 Jul;55(7):1946-53.PMID: 16804062 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy.

    Ilnytska O, Lyzogubov VV, Stevens MJ, Drel VR, Mashtalir N, Pacher P, Yorek MA, Obrosova IG.

    Diabetes. 2006 Jun;55(6):1686-94.PMID: 16731831 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.

    Cameron NE, Cotter MA, Basso M, Hohman TC.

    Diabetologia. 1997 Mar;40(3):271-81.PMID: 9084964 [PubMed - indexed for MEDLINE]Related articles

    15.

    Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy.

    Li F, Drel VR, Szabó C, Stevens MJ, Obrosova IG.

    Diabetes. 2005 May;54(5):1514-22.PMID: 15855340 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.

    Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Salvemini D, Yorek MA.

    Br J Pharmacol. 2001 Sep;134(1):21-9.PMID: 11522593 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Poly(ADP-ribose)polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats.

    Drel VR, Xu W, Zhang J, Kador PF, Ali TK, Shin J, Julius U, Slusher B, El-Remessy AB, Obrosova IG.

    Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1778-90. Epub 2008 Dec 20.PMID: 19098320 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.

    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.

    Diabetes Res Clin Pract. 2000 Oct;50(2):77-85.PMID: 10960717 [PubMed - indexed for MEDLINE]Related articles

    19.

    Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.

    Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, Mirrlees DJ.

    Diabetologia. 1994 Jul;37(7):651-63.PMID: 7958535 [PubMed - indexed for MEDLINE]Related articles

    20.

    Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst.

    Obrosova IG, Mabley JG, Zsengellér Z, Charniauskaya T, Abatan OI, Groves JT, Szabó C.

    FASEB J. 2005 Mar;19(3):401-3. Epub 2004 Dec 20.PMID: 15611153 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity